Research programme: multi-specific antibody therapeutics - Zyngenia

Drug Profile

Research programme: multi-specific antibody therapeutics - Zyngenia

Alternative Names: Zybodies™; Zybody™

Latest Information Update: 09 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zyngenia
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 09 Sep 2010 Zygenia raises $US15 million in Series A financing
  • 04 Nov 2009 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 04 Nov 2009 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top